RxDoctor Payments Data

Candace Wooten-Reed

Medical · Atlanta, GANPI 1750529764

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 539 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,304 and has fallen 67.2% since, to $1,084 in 2025. Among medical clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,028in general payments, 2019–2025

Across 539 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$975
  • Biohaven Pharmaceuticals, Inc.$819
  • GSK$570
  • Lilly USA, LLC$550
  • Amgen$516
  • plus $5K from 51 others

What the payments were for

  • Consulting fees$8008%
  • Food & beverage$9,22892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,028 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$76,616
JanuviaSitagliptin Phosphate38$56,273
OzempicSemaglutide41$55,668
FarxigaDapagliflozin Propanediol49$55,275
XareltoRivaroxaban40$54,919
TrulicityDulaglutide23$42,206
JardianceEmpagliflozin36$40,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$33,141
LinzessLinaclotide22$27,647
MounjaroTirzepatide14$18,612
TradjentaLinagliptin11$13,647
SymbicortBudesonide/Formoterol Fumarate13$3,343
Metoprolol Succinate189$3,145
Nifedipine ErNifedipine94$3,101
Albuterol Sulfate HfaAlbuterol Sulfate95$3,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$76,61683 claims
Lilly USA, LLCTrulicity, Mounjaro$550$60,81937 claims
AstraZenecaFarxiga, Symbicort$489$58,61862 claims
MerckJanuvia$167$56,27338 claims
Novo NordiskOzempic$975$55,66841 claims
Johnson & JohnsonXarelto$16$54,91940 claims
Boehringer IngelheimJardiance, Tradjenta$207$53,66247 claims
GSKTrelegy Ellipta$570$33,14132 claims
AbbVieLinzess$1,714$27,64722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.

Other medical in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →